Dual intron-targeted CRISPR-Cas9-mediated disruption of the AML RUNX1-RUNX1T1 fusion gene effectively inhibits proliferation and decreases tumor volume in vitro and in vivo

Oncogenic fusion drivers are common in hematological cancers and are thus relevant targets of future CRISPR-Cas9-based treatment strategies. However, breakpoint-location variation in patients pose a challenge to traditional breakpoint-targeting CRISPR-Cas9-mediated disruption strategies. Here we pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Neldeborg, Signe, Soerensen, Johannes Frasez, Møller, Charlotte Thornild, Bill, Marie, Gao, Zongliang, Bak, Rasmus O., Holm, Kasper, Sorensen, Boe, Nyegaard, Mette, Luo, Yonglun, Hokland, Peter, Stougaard, Magnus, Ludvigsen, Maja, Holm, Christian Kanstrup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457201/
https://www.ncbi.nlm.nih.gov/pubmed/37464068
http://dx.doi.org/10.1038/s41375-023-01950-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457201/
https://www.ncbi.nlm.nih.gov/pubmed/37464068
http://dx.doi.org/10.1038/s41375-023-01950-9

Ejemplares similares